Menopause Practice: A Clinician’s Guide | Carolyn J. Crandall et al. | ResearchPod

Transcript: Menopause Practice: A Clinician’s Guide

Alex: Welcome to another episode of ResearchPod. Today we're looking at the clinical framework for managing menopause—specifically, how the field has moved away from treating it as a binary event and toward staging it as a multi-year physiological transition.

Sam: That binary framing is surprisingly persistent. You're either pre- or post-menopausal. But that can't be how the biology actually works.

Alex: It isn't. The North American Menopause Society's guidance is explicit on this: menopause is a continuum, not a threshold. And that distinction has real diagnostic consequences.

Sam: If it's a continuum, how do clinicians actually stage it? Is the instinct to just track FSH and call it done?

Alex: That instinct is exactly the problem. Single-point endocrine snapshots are unreliable during the transition because hormones like FSH fluctuate substantially—sometimes within the same cycle. You're sampling a noisy signal and treating it as ground truth.

Sam: It's like trying to gauge a car's fuel level by reading pressure in the fuel line while the engine is sputtering. The measurement is real, but it's not telling you what you think it's telling you.

Alex: That's a fair analogy. The STRAW+10 staging system—the current gold standard—addresses this by anchoring staging primarily in menstrual cycle patterns rather than hormone levels. Cycle history is a far more stable signal.

Sam: So the menstrual record does the heavy lifting, and endocrine markers are supplementary?

Alex: Exactly. FSH and AMH are informative, but they sit lower in the diagnostic hierarchy precisely because they're prone to within-person variability that makes them unreliable as primary anchors. The staging system integrates both, but menstrual history is load-bearing.

Sam: Why does that hierarchy matter clinically? What goes wrong if you get it backwards?

Alex: Consider a 44-year-old presenting with irregular cycles and mood disturbance. A single elevated FSH might reflect perimenopause, or it might be a transient spike. If you stage her on that reading alone, you risk misattributing her symptoms—or missing that she's in early perimenopause and needs a different management approach. The staging system forces you to integrate the full picture.

Sam: And the underlying biology is what makes this complicated. You mentioned the HPO axis operating in a kind of compensated failure mode—can you walk through the mechanism?

Alex: As ovarian reserve declines, the first hormones to drop are inhibin B and anti-müllerian hormone. Both normally act as brakes on FSH secretion. When that inhibition falls away, FSH rises—and that rise actually accelerates follicle recruitment. So paradoxically, you get a period of increased follicular activity even as the reserve is depleting. The system is working harder to compensate for what it's losing.

Menopause Practice: A Clinician’s Guide

Carolyn J. Crandall, Gloria A. Bachman, Stephanie S. Faubion, Wendy Klein, James H. Liu, JoAnn E. Manson, Joanne Mortimer, JoAnn V. Pinkerton, Nanette F. Santoro, Jan L. Shifren, Rebecca C. Thurston, Rebecca H. Allen, Idoroenyi Amanam, Dina N. Anderson, David F. Archer, Marcella Calfon Press, Janet S. Carpenter, Mihaela Cristea, Carrie Cwiak, Samar R. El Khoudary, Evyatar Evron, Marwan Fakih, Heather E. Fields, Carolyn Goh, Steven R. Goldstein, Jun Gong, Clarisa R. Gracia, Minda A. Green, Tamara B. Horwich, Lina Huang, Michelle Jacobson, Jae Jung, Risa Kagan, Scott Kahan, Andrew M. Kaunitz, Susan Kellogg Spadt, Anita M. Kelsey, Sheryl A. Kingsberg

Sep 8, 2026·4:04·user_upload

Menopause ManagementClinical Practice GuidelinesHormone TherapyWomen's HealthContinuing Medical Education (CME)Pharmacotherapeutics

Listen

4 min

Briefing

Overview of Menopause Management

Menopause is a universal experience for women, yet the clinical management of the transition requires a nuanced understanding of hormonal, physical, and psychosocial changes. This guide serves as a definitive resource for healthcare providers, offering a structured approach to diagnosing menopause, assessing health risks, and tailoring therapeutic interventions. By utilizing the STRAW+10 staging system, clinicians can better categorize a patient's reproductive status, which is essential for determining appropriate care.

The Menopause Transition

The transition is defined by a decline in ovarian function, characterized by irregular menstrual cycles and fluctuating hormone levels. The guide highlights that chronologic age is a poor predictor of reproductive senescence. Instead, clinicians are encouraged to use menstrual-cycle patterns and, where appropriate, endocrine markers to stage patients. Understanding these stages is critical, as the transition often brings significant symptoms—such as vasomotor symptoms, sleep disturbances, and genitourinary changes—that impact quality of life.

Clinical Assessment and Treatment

Effective management requires a thorough clinical assessment to identify contraindications to therapy and to address common midlife conditions like osteoporosis, cardiovascular disease, and metabolic disorders. The guide details a wide range of management options, including prescription therapies such as estrogen and estrogen-progestogen therapy, while emphasizing the importance of lifestyle counseling. It also provides clear guidance on managing primary ovarian insufficiency (POI) and early menopause, advocating for hormone replacement until the average age of natural menopause to mitigate long-term health risks.

Why It Matters

As life expectancy increases, women will spend a significant portion of their lives in the postmenopausal stage. Providing evidence-based, individualized care is essential to improve health outcomes and quality of life during this period. This guide empowers clinicians to move beyond generic advice, fostering a collaborative relationship with patients to navigate the complexities of midlife health.

Key Terms and Definitions

STRAW+10 — The gold-standard staging system that characterizes reproductive aging from the reproductive years through menopause using menstrual-cycle and endocrine criteria.
Primary Ovarian Insufficiency (POI) — A clinical entity characterized by hypergonadotropic hypogonadism in women younger than 40, previously referred to as premature ovarian failure.
Vasomotor Symptoms (VMS) — Common menopause-related symptoms, such as hot flashes and night sweats, resulting from the decline in ovarian function.
Luteal Out-of-Phase (LOOP) Event — A physiological phenomenon during the menopause transition where elevated FSH levels recruit a second follicle during the luteal phase, leading to atypical estradiol secretion.
Climacteric — The period of endocrinologic, somatic, and transitory psychological changes occurring at the time of menopause.

Menopause Practice: A Clinician’s Guide: Research Paper Podcast